Results 281 to 290 of about 177,994 (348)

A phase 1 study of ASTX727 plus talazoparib in patients with triple‐negative or hormone resistant/HER2‐negative metastatic breast cancer

Cancer, Volume 132, Issue 8, 15 April 2026.
Abstract Background Poly(adenosine diphosphate ribose) polymerase (PARP) is recruited to DNA damage sites along with epigenetic factors such as DNA methyltransferase 1 (DNMT1). Inhibitors of DNMT modulate reactive oxygen species (ROS)‐cyclic adenosine monophosphate (cAMP)/Protein Kinase A signaling and induce a “BRCAness phenotype” that further ...
Kathy D. Miller, Alexandra Thomas, Sandra Althouse, Yong Zang, Erin Conder, Ryan Burgos, Bryan P. Schneider, Tarah Ballinger, Emily Douglas, Katherine Ansley, H. Josh Jang, Woonbok Chung, Jean‐Pierre Issa, Kenneth P. Nephew, Feyruz V. Rassool   +14 more
wiley   +1 more source

Targeting the RXR Pathway for the Prevention of Triple-Negative Breast Cancer. [PDF]

Cancer Prev Res (Phila)
Moyer CL, Hill JL, Coleman D, Lanier A, Ma Y, Liu X, Kawedia J, Contreras A, Vuligonda V, Savage MI, Sanders ME, Mohammed A, Sei S, Brown PH, Mazumdar A.   +14 more
europepmc   +1 more source

Challenges in the future of cancer screening

International Journal of Cancer, Volume 158, Issue 8, Page 2013-2022, 15 April 2026.
Abstract The purpose of cancer screening is to reduce mortality, and ideally incidence, from the cancer screened for. Until recently, cancer screening has been offered to all persons in pre‐defined sex‐ and age‐groups. The exception is lung screening which is targeted to high‐risk individuals.
Elsebeth Lynge, Berit Andersen, Stig E. Bojesen, Lone Kjeld Petersen, Mickael Bech, Martin Bøgsted, Mie Seest Dam, Søren Egstrand, Anne Mette Fløe Hvass, Camilla J. Kobylecki, Kristina Lång, Mads Nielsen, Giorgi Paolo Rossi, Michael Stenger, Ilse Vejborg, Future of Cancer Screening Working Group, Vibe Munk Bertelsen, Janne Bigaard, Karen Omann Binderup, Lennart Friis‐Hansen, Stine Bisgaard Greve, Jessica Xin Hjaltelin, Rikke Hedegaard Jensen, Gitte Jessing, Pia Kirkegaard, Mette Hartmann Nonboe, Tina Bech Olesen, Katrine Stolberg, Signe Bülow Therkildsen, Mette Kielsholm Thomsen   +29 more
wiley   +1 more source

Targeting poly(ADP-ribose) polymerase in metastatic prostate cancer: current landscape and future directions. [PDF]

Curr Opin Oncol
Shi X, Rifai S, Meher Z, Hussain A.
europepmc   +1 more source

A rare case of uterine carcinosarcoma in a 21-year-old woman with hereditary breast and ovarian cancer syndrome: A case report. [PDF]

Oncol Lett
Iida Y, Kosuge A, Saito Y, Irie T, Matsushima J, Iizuka M, Takakura S.   +6 more
europepmc   +1 more source

Editorial: Molecular studies and therapeutic approaches on BRCA-associated cancers. [PDF]

Front Mol Biosci
Bhat A, Wang X, Stephen P.
europepmc   +1 more source

The mitochondrial translocation of phosphorylated EZH2 promotes PARP inhibitor resistance in BRCA1-deficient epithelial ovarian cancer. [PDF]

Cell Discov
Hu L, Ma X, Cai X, Yan T, Zhou K, Shan C, Guo N, Zheng H, Wang Y, Tong Y, Xie S, Zhang H, Chen C, Gong Z, Guo L, Lu R.   +15 more
europepmc   +1 more source

Oncogenetic testing and follow-up for women with familial breast/ovarian cancer, Li-Fraumeni syndrome and Cowden syndrome [PDF]

, 2015
't Kint de Roodenbeke, Daphné, Berlière, Martine, Claes, Kathleen, Hulstaert, Frank, Janin, Nicolas, Matthijs, Gert, Poppe, Bruce, Robays, Jo, Stordeur, Sabine, Van Maerken, Tom, Wildiers, Hans   +10 more
core  

Assessment of Homologous Recombination System Gene Expression in Chemologically Induced Carcinogenesis In Vivo Models. [PDF]

Curr Issues Mol Biol
Tsyganov MM, Bulatova DZ, Fedorenko AA, Loos DM, Nikiforov PE, Tsydenova IA, Bayanbayeva AA, Sharipkhanova Z, Timoshenko SS, Ibragimova MK.   +9 more
europepmc   +1 more source